SCHEMBL5541926

SCHEMBL5541926

Oc1ccc(N2CCN(CCCCCc3ccc(C(F)(F)F)cc3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.57
ME2 P23368 1/20 0.56
ME1 P48163 1/20 0.56
ME3 Q16798 1/20 0.56
DRD2 P14416 6/20 0.55
HTR1A P08908 5/20 0.55
HTR2A P28223 5/20 0.55
DRD3 P35462 3/20 0.55
TMEM97 Q5BJF2 2/20 0.55
DRD1 P21728 1/20 0.55
DRD5 P21918 1/20 0.55
DRD4 P21917 2/20 0.54
SLC6A4 P31645 3/20 0.52
SLC6A2 P23975 2/20 0.52
ADRA1D P25100 1/20 0.52
ADRA1A P35348 1/20 0.52
ADRA1B P35368 1/20 0.52
HTR7 P34969 3/20 0.51
HTR2C P28335 1/20 0.51
HRH1 P35367 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537517 1.00 SIGMAR1 (0.57) SIGMAR1ME2ME1ME3DRD2
SCHEMBL5539612 0.99 SIGMAR1 (0.58) SIGMAR1ME2ME1ME3DRD2
SCHEMBL5536064 0.95 ME2 (0.58) SIGMAR1ME2ME1ME3DRD2
SCHEMBL5547210 0.90 ADRA1D (0.62) SIGMAR1ME2ME1ME3DRD2
SCHEMBL5537510 0.88 SIGMAR1 (0.57) SIGMAR1DRD2HTR1AHTR2ADRD3
SCHEMBL5541921 0.88 SIGMAR1 (0.57) SIGMAR1DRD2HTR1AHTR2ADRD3
SCHEMBL30671730 0.87 SIGMAR1 (0.73) SIGMAR1DRD2HTR1AHTR2ADRD3
SCHEMBL5539608 0.86 SIGMAR1 (0.58) SIGMAR1DRD2HTR1AHTR2ADRD3
SCHEMBL5544228 0.84 SIGMAR1 (0.52) SIGMAR1DRD2HTR1AHTR2ADRD3
SCHEMBL5540600 0.84 SIGMAR1 (0.52) SIGMAR1DRD2HTR1AHTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SIGMAR1 234/4885ME2 561/4885ME1 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.